The cancer–immune dialogue subject to immuno-oncological intervention is profoundly
influenced by microenvironmental factors. Indeed, the mucosal microbiota—and more …

The past decade has witnessed groundbreaking advances in the field of microbiome
research. An area where immense implications of the microbiome have been demonstrated …

Background The gut microbiota is reportedly involved in the progression and
chemoresistance of various human malignancies. However, the underlying mechanisms …

Purpose: Emerging evidence indicates that gut microbiota dysbiosis can reduce the
effectiveness of immune checkpoint inhibitors (ICI). Proton pump inhibitors (PPI) are known …

Abstract Background Proton pump inhibitors (PPIs) are commonly used concomitant to
cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in the last decade.
Among various checkpoints identified so far, interaction between programmed death-1 (PD …

Introduction Gut dysbiosis may reduce immune checkpoint inhibitor (ICI) efficacy. Antibiotics
and proton pump inhibitors (PPIs) are commonly used drugs causing gut dysbiosis. There is …

Immunotherapy is one of the fastest developing areas in the field of oncology. Many
immunological treatment strategies for refractory tumors have been approved and marketed …

Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced
urothelial cancer. However, a significant number of patients do not respond to ICI, and the …

In locally advanced and metastatic malignancies, antibiotic (ATB) therapy has a negative
effect on immunotherapy efficacy. Therefore, we aimed to evaluate whether ATB therapy and …